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Abstract
Background: Our purpose was to collect preliminary data on newly diagnosed breast cancer
patient knowledge of prognosis before and after oncology visits. Many oncologists use a validated
prognostic software model, Adjuvant!, to estimate 10-year recurrence and mortality outcomes for
breast cancer local and adjuvant therapy. Some oncologists are printing Adjuvant! screens to use
as visual aids during consultations. No study has reported how such use of Adjuvant! printouts
affects patient knowledge of prognosis. We hypothesized that Adjuvant! printouts would be
associated with significant changes in the proportion of patients with accurate understanding of
local therapy prognosis.
Methods: We recruited a convenience sample of 20 patients seen by 2 senior oncologists using
Adjuvant! printouts of recurrence and mortality screens in our academic medical center. We asked
patients for their estimates of local therapy recurrence and mortality risks and counted the number
of patients whose estimates were within ± 5% of Adjuvant! before and after the oncology visit,
testing whether pre/post changes were significant using McNemar's two-sided test at a significance
level of 5%.
Results: Two patients (10%) accurately estimated local therapy recurrence and mortality risks
before the oncology visit, while seven out of twenty (35%) were accurate afterwards (p = 0.125).
Conclusion: A majority of patients in our sample were inaccurate in estimating their local therapy
recurrence and mortality risks, even after being shown printouts summarizing these risks during
their oncology visits. Larger studies are needed to replicate or repudiate these preliminary findings,
and test alternative methods of presenting risk estimates. Meanwhile, oncologists should be wary
of relying exclusively on Adjuvant! printouts to communicate local therapy recurrence and
mortality estimates to patients, as they may leave a majority of patients misinformed.
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In 2007, an estimated 178,480 new cases of invasive
breast cancer were diagnosed among US women and
approximately 40,460 died from the disease [1]. To
reduce the risks of progression, recurrence, and ultimately
mortality, adjuvant therapies such as chemotherapy and
hormone therapy are often recommended in addition to
local therapies such as surgery and radiation.
These therapies have uncertain outcomes. For example,
prior studies indicate that some chemotherapy regimens
carry approximately a 0.5% chance of treatment-induced
leukemia [2] in addition to increases in 10-year absolute
survival ranging from 2–11% for most breast cancer
patients [3]. Oncologists must communicate these and
other uncertain outcomes to patients in order to assure
that treatment decisions are made based on valid informa-
tion and well-considered preferences.
Risk communication includes, among other elements,
"information about the nature and likelihood" of key out-
comes of interest [4]. In order to facilitate oncologist com-
munication about the likelihoods of treatment outcomes,
researchers have created prognostic models based on reg-
istry outcomes data and evidence from clinical trials. One
such model, Adjuvant!, is used by 44% of community
oncologists and 78% of clinical research oncologists "to
estimate breast cancer patients' risk of recurrence and/or
mortality [5]." Adjuvant! forecasts recurrence and mortal-
ity risks based on specific patient and tumor characteris-
tics, and estimates the treatment benefit of various
treatment options, ranging from local therapy only to
combined chemotherapy and hormone therapy [6-8].
Adjuvant! has been validated against a Canadian database
of outcomes [9].
Some oncologists have begun printing screenshots from
the Adjuvant! risk estimation tool, and discussing the esti-
mates with patients during oncology visits. One study has
documented that this practice is associated with fewer
early-stage patients choosing chemotherapy [10,11]. It is
not known, however, whether Adjuvant! printouts
achieve their intended purpose of informing breast cancer
patients about the likelihood of 10-year recurrence and
mortality outcomes. Therefore, we embarked on a pilot
study to collect preliminary data about patient knowledge
regarding local therapy recurrence and mortality risks, and
whether patient knowledge might be influenced by oncol-
ogist use of Adjuvant! printouts during the oncology visit.
We focused in this study on local therapy prognosis, i.e.
Adjuvant!'s 10-year recurrence and survival estimates,
because these estimates represent a baseline that patients
should understand in order to make informed decisions
about whether to take systemic adjuvant therapy.
We hypothesized that Adjuvant! printouts in the context
of an oncology visit should be associated with significant
changes in the proportion of patients with accurate under-
standing of local therapy prognosis. We were open to the
possibility that patients might be more confused than
enlightened by Adjuvant!'s screens, which were originally
designed as a reference tool for oncologists.
We asked two questions about patient estimates of local
therapy recurrence and mortality rates:
1. Did patient estimates of local therapy recurrence and
mortality risks match Adjuvant! estimates before the
oncology visit?
2. Did patient estimates of local therapy recurrence and
mortality risks move closer to Adjuvant! after the oncol-
ogy visit?
Our study is the first to report on patient knowledge of
local therapy recurrence and mortality risks in the context
of using Adjuvant!
Methods
Study design and settings
The study design was a single-arm, exploratory, hypothe-
sis-generating pilot study of a convenience sample of 20
consecutive patients consulting two senior medical oncol-
ogists at the University of California, San Francisco
(UCSF) Breast Care Center after having seen one surgeon.
The study was approved by the UCSF Committee on
Human Research and the Department of Defense Human
Subjects Research Review Board, and informed consent
was obtained from each participant. The consent form
explained that patients would receive printed, quantita-
tive information about their prognosis under different
treatment scenarios, and alerted them that they would be
asked to complete a short questionnaire assessing their
understanding of the materials. Patients were not primed
as to the specifics of the measurements or instruments.
The two participating oncologists were involved in the
general design of the study, including the selection of the
primary outcome and measure of patient knowledge.
Prior to the study, the oncologists caucused to standardize
their use of the intervention. They agreed to see all study
patients in 60 minute visits. Half of each visit was devoted
to history taking, a physical exam, and disclosure of treat-
ment risks and side effects. The oncologists presented con-
sistent information about treatment risks and side effects
based on systematic reviews. The second half of the visit
was devoted to reviewing Adjuvant! printouts showing
recurrence and mortality rates as a function of the
patient's situation, and answering patient questions about
the printouts. Patients were eligible to participate in thePage 2 of 8
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completed surgery for stage I, II, or IIIa breast cancer, if
they had not initiated any form of adjuvant therapy, and
if their medical charts included tumor size, tumor grade,
hormone receptor status, node status, and age. Patients
were not eligible to participate in the study if they had
metastatic disease, if they needed further surgery to com-
plete staging, or if they were unable to provide informed
consent. Patients were enrolled between October, 2001
and February, 2002. (Figure 1)
Intervention and procedures – Adjuvant! printouts
The intervention in this single-arm, pre/post study con-
sisted of a printout of the graphs from the Adjuvant! soft-
ware program, which presented estimates of the patient
prognosis based on patient-specific inputs consisting of
age, tumor size and grade, estrogen receptor status, node
status, and number of comorbidities. (See Figure 2). A
study coordinator generated the printout upon configur-
ing the Adjuvant! inputs in discussion with the oncologist
prior to the patient-oncologist consultation. During the
patient-oncologist visit, each of the two oncologists used
the printout as a visual aid to communicate mortality and
recurrence information.
Outcomes and instruments
Our primary outcome was patient knowledge of both
recurrence and mortality risks because, although these
outcomes are correlated, patients experience recurrence as
being a threat to quality of life in addition to mortality
being a threat to length of life. We focused on local ther-
apy prognosis (prognosis after surgery with or without
radiation) because this represents a baseline from which
patients and doctors should weigh the further benefits
and risks of adjuvant chemotherapy or hormone therapy.
We focused on an accuracy standard of ± 5% absolute per-
centage points because Adjuvant! was found in a valida-
tion study to be accurate within 2–5% in estimating local
and adjuvant therapy mortality and recurrence risks for a
broad range of breast cancer cases [9]. In addition, 10-year
absolute mortality benefits of chemotherapy range from 2
to 11% for a wide range of breast cancer cases [3]. There-
fore we selected ± 5% as a clinically significant threshold
representing the maximum allowable margin of error.
The instrument for measuring patient beliefs regarding
10-year recurrence and mortality risks was a survey
administered before and after the patient-oncologist con-
sultation. The items included:
The chance of my breast cancer returning or spreading within
the next 10 years after having local therapy is...
The chance that I will die from my breast cancer within the next
10 years after having local therapy is...
The response format was a list of 21 potential responses
(0%, 5%, 10%, ... to 100% in increments of 5%).
Analyses
1. Did patient estimates of local therapy recurrence and mortal-
ity match Adjuvant! estimates before the oncology visit?
To answer this question, we calculated the difference
between Adjuvant! and patient estimates and assessed the
number of patient estimates that were within ± 5% of
their Adjuvant! estimate.
2. Did patient estimates of local therapy recurrence and mortal-
ity move closer to Adjuvant! after the oncology visit?
We used McNemar's test to assess the degree to which the
patient estimates improved. McNemar's test compares the
number who improved with the number that got worse,
with respect to our ± 5% accuracy threshold. It uses the
Binomial distribution to test whether the number of
improved estimates is equal to the number that got worse,
where the number of trials is the total of improvements
and deteriorations; improvement is a success; and the
probability of success is 0.5 under the null hypothesis.
For both study questions, we performed sensitivity analy-
sis on our definition of accuracy, testing the robustness of
our findings under scenarios where we focused on recur-
rence alone, mortality alone, and either recurrence or
mortality. We also performed sensitivity analysis on our
accuracy threshold to establish whether our findings for
pre-visit patient beliefs were different for a margin of ±
10% than for ± 5%. Finally, we conducted two-way sensi-
Study schemaFigure 1
Study schema. Study schema showing chronological steps 
in this pre/post single-arm study.Page 3 of 8
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of accuracy and the threshold.
Results
Sample
Twenty out of 21 consecutive, eligible women consented
after being offered participation in this study. The woman
who did not participate did not state a reason for declin-
ing. Eighteen women (90%) were White and most (n =
17, 85%) were U.S.-born. Their ages ranged from 40 to 76
years old, with a median age of 54 years. A plurality of
respondents were married or were living with a partner (n
= 15, 75%), were college graduates (n = 9, 45%), were
employed full-time (n = 10, 50%), and had an annual
family income between $75,000 and $150,000 (n = 7,
35%). The two attending oncologists participating in the
study (including author HSR) confirmed that all of the
consenting patients fell into the subgroups for which
Adjuvant!'s accuracy had been validated as being within
5% [9].
Table 1 enumerates the recurrence and mortality esti-
mates, respectively, for the 20 patients. The Adjuvant!
model forecasted a broad range of local therapy recur-
rence and mortality estimates, displayed by increasing
recurrence risk in the second column of Table 1. This
range reflected the heterogeneity of our participants with
respect to age, tumor size, tumor grade, node involve-
ment, hormone receptor status, and comorbidities.
Analysis
1. Did patient estimates of local therapy recurrence and mortal-
ity match Adjuvant! estimates before the oncology visit?
Before the visit, 2 patients out of 20 were within ± 5% of
their Adjuvant! estimates for both recurrence and mortal-
ity.
Sensitivity Analysis
Table 2 summarizes our analysis of sensitivity to the 5%
threshold for patient estimates before the oncology visit.
Changing the ± 5% margin of accuracy to ± 10% resulted
in 2 more patients matching Adjuvant! on both recur-
rence and mortality estimates before the oncology visit.
Screenshot of the Adjuvant! software programFigure 2
Screenshot of the Adjuvant! software program. The two oncologists in this study used Adjuvant! to generate prognostic 
estimates tailored to patient information shown in the upper left of the screen. Oncologists printed screenshots showing 
patient recurrence (relapse) or mortality, selected at bottom right, for "no additional therapy", top right.Page 4 of 8
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tality estimates separately. Before their visit, for recur-
rence, 6 patients out of 20 were accurate within ± 5% of
their Adjuvant! estimate. For mortality, 5 patients out of
20 were accurate within ± 5% of their Adjuvant! estimate
before their oncology visit. Finally, we analyzed patient
performance in estimating either recurrence or mortality.
At the ± 5% accuracy threshold, 9 patients were accurate
before on either one or the other or both.
2. Did patient estimates of local therapy recurrence and mortal-
ity move closer to Adjuvant! after the oncology visit?
Seven patients ended up within the ± 5% accuracy thresh-
old on both recurrence and mortality estimates. Of the
two who started matched within ± 5% of Adjuvant! before
the oncology visit, one of them became mismatched, but
6 of the 18 who started mismatched moved into agree-
ment with Adjuvant!, for a net total of 7 accurate patient
estimates after the visit (p = 0.125, McNemar's test, based
on the 6 of 7 who improved rather than worsened in accu-
racy).
Sensitivity Analysis
At a threshold of ± 10%, 13 matched Adjuvant! after the
oncology visit for both recurrence and mortality esti-
mates. At this threshold, the McNemar test for improve-
ment was significant (p = 0.012, based on 10 of 11 who
improved rather than worsened).
Regarding estimates of recurrence alone, 12 patients
ended up within the ± 5% threshold after the visit. Of the
6 who started matched, 3 became mismatched, while 9 of
the 14 who started mismatched, became matched (p =
0.146 by McNemar's test). Regarding estimates of mortal-
ity alone, 10 patients ended up within the ± 5% accuracy
threshold for mortality estimates. Of the 5 who started
matched before, 1 became mismatched, while 6 of the 15
who started mismatched, became matched (p = 0.125 by
McNemar's test.)
We also analyzed patient performance in estimating either
recurrence or mortality after the visit. At the ± 5% thresh-
Table 1: Local therapy recurrence and mortality estimates

















6 12 5 50 -7 38 39 5 50 -34 11
11 13 90 5 77 -8 4 10 0 6 -4
12 14 50 10 36 -4 9 30 5 21 -4
19 14 10 20 -4 6 28 10 10 -18 -18
10 15 15 20 0 5 6 10 10 4 4
3 15 10 50 -5 35 12 10 20 -2 8
20 16 30 15 14 -1 8 20 0 12 -8
5 17 15 25 -2 8 22 5 20 -17 -2
16 18 30 15 12 -3 14 30 10 16 -4
17 19 30 20 11 1 8 10 5 2 -3
2 20 95 20 75 0 9 90 0 81 -9
4 21 30 20 9 -1 15 10 20 -5 5
8 24 40 20 16 -4 13 10 10 -3 -3
18 26 30 25 4 -1 17 10 10 -7 -7
9 33 90 65 57 32 24 90 75 66 51
1 34 20 10 -14 -24 23 5 10 -18 -13
13 39 0 40 -39 1 27 0 25 -27 -2
7 40 30 40 -10 0 28 10 40 -18 12
15 53 70 70 17 17 41 70 40 29 -1
14 95 100 90 5 -5 89 100 80 11 -9
This table shows the difference between patient Adjuvant! estimates, 
before and after the oncology visit. Patient estimates highlighted in 
boldface are within ± 5% of Adjuvant! Abbreviations are ID for study 
identification number, A! for Adjuvant!, P for patient, (B) for before 
the visit, and (A) for after the visit.
Table 2: Sensitivity analysis of threshold for margin of error and outcome measure
Recurrence and mortality
Threshold (±) Right before Wrong before Stayed right Stayed wrong Got right Got wrong Right after Wrong after McNemar p-
value
5% 2 18 1 12 6 1 7 13 0.125
10% 4 16 3 6 10 1 13 7 0.012
Recurrence
5% 6 14 3 5 9 3 12 8 0.146
10% 9 11 7 3 8 2 15 5 0.109
Mortality
5% 5 15 4 9 6 1 10 10 0.125
10% 7 13 7 5 8 0 15 5 0.008
Recurrence or Mortality
5% 9 11 7 3 8 2 15 5 0.110
10% 12 8 11 2 6 1 17 3 0.125
This table shows how results change moving from a ± 5% to a ± 10% accuracy threshold within an outcome measure, and how results change 
depending on which outcome measure is the focus of the analysis.Page 5 of 8
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Our purpose was to generate preliminary results regarding
patient beliefs about 10-year local therapy recurrence and
mortality risks, before and after the use of Adjuvant! print-
outs during oncology consultations. Based on this study,
we conclude:
1. A majority of breast cancer patients were inaccurate (i.e.
beyond ± 5%) in their estimates of local therapy recur-
rence and mortality before seeing an oncologist who used
Adjuvant! printouts;
2. The oncology visit including Adjuvant! printouts did
not significantly improve the proportion who were accu-
rate after compared to before the visit;
3. A majority of patients were inaccurate (beyond ± 5%)
in their estimates of local therapy recurrence and mortal-
ity after visiting an oncologist who used Adjuvant! print-
outs.
Interpretations
Our first and third findings suggest that oncologists may
not be able to rely on their current practices, including
printing Adjuvant! screenshots, to educate a majority of
their patients to an appropriate degree of accuracy about
their recurrence and mortality risks.
Our second finding is likely an artifact of our small sam-
ple size. Our results did suggest improvement in the
number of patients with accurate estimates for one, either,
or both recurrence and mortality outcomes.
Our findings also depend on three critical assumptions.
First, we assume that Adjuvant! is indeed a gold standard
for 10-year local therapy outcomes against which patient
estimates can be evaluated. All three of our findings are
sensitive to this assumption.
A second assumption is that patient estimates need to be
within ± 5% of their surgery recurrence and mortality risks
in order to be considered accurate. If we relax the thresh-
old for accuracy from ± 5% to ± 10%, our study does
detect a statistically significant improvement in the
number of patients with accurate estimates where no such
statistical improvement exists with the more stringent
accuracy threshold. Therefore our second finding is sensi-
tive to this assumption.
Third, we assume that patients need to understand both
recurrence and mortality risks associated with local ther-
apy, because recurrence affects quality while mortality
affects quantity of life. Our insistence on including both
outcomes increases expectations for risk communication
compared to focusing on either recurrence or mortality
alone. For example, in our study, only seven patients accu-
rately estimated both recurrence and mortality risks after
seeing their oncologist. However, 12 were accurate on
recurrence afterwards and 10 were accurate on mortality
afterwards. Therefore our third finding, that a majority of
patients remain inaccurate, depends on whether patients
need to know both recurrence and mortality, or one, or
either.
Study quality
This is the first detailed report of patient estimates about
local therapy prognosis in the context of oncologists using
Adjuvant! printouts as a teaching tool during the oncol-
ogy visit. We have previously reported methodological
insights from this study [12,13] and we have written an
editorial about some of the implications [14]. Other stud-
ies have reported on the use of Adjuvant! but not its influ-
ence on patient knowledge [10,11]. A recent study
simulated the hypothetical use of the Adjuvant! interface
in an internet survey of women, but these women were
not being treated for breast cancer [15] Another has
reported on the impact of another decision aid (the Deci-
sion Board) on patient knowledge, but the Decision
Board focuses on 5-year outcomes for recurrence only
[16]. Our findings provide some preliminary, quantitative
evidence that patients were not adequately informed
about their local therapy prognoses before meeting with
oncologists; and that the use of a validated and widely dis-
seminated oncologist reference tool was not sufficient to
adequately educate a majority of patients about their local
therapy prognoses.
However, this study was subject to biases and its results
should only be interpreted with an orientation to prelim-
inary findings and hypothesis generation. This was a pre/
post single-sample design, with no control group, so we
cannot be sure that any changes in accuracy of patient esti-
mates were due to use of the Adjuvant! printouts com-
pared to other aspects of the oncology visit. The sample
was small, so the study was underpowered to rule out the
role of chance in producing apparent changes before and
after the oncology visits. We asked patients only about
their beliefs, so we cannot rule out the possibility that they
could accurately recall risk estimates but did not believe
them. We used a categorical response format that limited
the resolution of patient estimates to 5% increments. This
study was conducted before the availability of biologic
therapies and genetic risk assessment tests. Our report
does not focus on other aspects of the oncology visit,Page 6 of 8
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mortality, and side effect rates.
Connections to the literature
This being the first report examining patient knowledge
before and after exposure to Adjuvant!, there are no
directly comparable studies of Adjuvant! against which to
triangulate our findings and interpretations. However, in
a study of risk communication using an alternative to
Adjuvant!, Whelan and colleagues tested a Decision Board
that presented 5-year recurrence risk estimates (derived
from registry data) to node-negative breast cancer
patients. Thirty-one out of 92 patients in the control arm
came within ± 10% of the gold standard estimates for
recurrence risk without chemotherapy [16]. Therefore,
under usual care conditions, most breast cancer patients
did not match gold standard 5-year recurrence risk esti-
mates, even with a ± 10% accuracy threshold. We also
found that a majority of patients (9 out of 20) unexposed
to a decision aid (in our study, at baseline) did not match
10-year recurrence risk estimates within ± 10%.
In the Decision Board intervention group, 49 out of 82
(60%) matched the gold standard within ± 10%, which
was a significant improvement compared to the control
group (31 out of 92 or 34%, p < 0.001). We also found an
improvement in recurrence estimates, from 9/20 before to
15/20 after, at the ± 10%, although this was not statisti-
cally significant in our study. The authors did not report
sensitivity analysis to their accuracy threshold, and so we
cannot compare findings at our more stringent, and we
believe more clinically appropriate, threshold of ± 5%.
Our findings are also consistent with the literature on risk
communication outside of adjuvant therapy for breast
cancer. Generally, people have difficulty retaining and
recalling probabilities [4]. The Adjuvant! interface was
designed before the emergence of best practices regarding
the use of graphical formats in risk communication
[17,18]. A recent internet survey randomized women at
risk for breast cancer to either the Adjuvant! interface, ver-
sus interfaces that incorporated best practices in risk com-
munication, and found significant improvements in
retention and recall of likelihoods [15]. Our findings can
also be linked to theoretical constructs. Risk estimates
about local therapy prognosis are available from special-
ized sources such as Adjuvant!, and systematic reviews
such as the Early Breast Cancer Trialists' Collaborative
Group [19]. However, surgeons and others may not be
communicating these estimates to patients before they
arrive at their oncology visit, reflecting an implementation
gap. This would partially explain why only 2 patients were
well-informed about local therapy prognosis before their
oncology visit.
Those patients (18 in our sample) who are inadequately
informed before their oncology visit may face significant
emotional and cognitive barriers to absorbing informa-
tion presented during the visits [20,21]. Furthermore,
even if they could overcome these barriers, they may not
be the kind of information seekers who want to absorb
prognostic information [22,23].
Those patients who do seek prognostic information may
experience overload as they are presented with recurrence,
mortality and side effect rates associated with hormone
therapy, chemotherapy, and combined hormone and
chemotherapy treatment options, as well as the local ther-
apy baseline. For example, patients in our sample were
better able to estimate one or the other risk estimate after
their oncology visit than both together. Also, the Adju-
vant! interface was initially designed for use by oncolo-
gists, and its bar charts and other formats may not be
comprehensible or memorable enough for patients.
Finally, patients may not believe the information they are
being presented. The discrepancy between their estimates
and those provided by Adjuvant! may arise from the fact
that patients may feel more optimistic or more pessimistic
about their chances, and may adjust their estimates
accordingly.
Conclusion
Our study found that whether we hold patients to an accu-
racy threshold of ± 5% or ± 10% on recurrence, mortality,
or both outcomes, changes our evaluation of Adjuvant!
printouts. Oncologists and researchers therefore need to
agree on clinically relevant thresholds for accuracy in risk
communication, and on whether patients need to under-
stand both recurrence and mortality risks (along with side
effects).
Pending further studies and progress, oncologists should
be aware that relying exclusively on Adjuvant! printouts to
communicate both recurrence and mortality estimates to
patients may leave a majority of patients misinformed.
Oncologists may wish to focus initially on either recur-
rence or mortality, check with patients for understanding,
and then assess with patients whether additional informa-
tion will result in overload. Finally, oncologists should
initiate or participate in research to replicate or repudiate
our findings, and experiment with alternative approaches.
For example, the developers of Adjuvant! could experi-
ment with revising the software's interface to reflect the
latest findings in graphical display of risk information
[15].
Oncologists face the daunting task of communicating
recurrence and mortality risks, for local therapy, chemo-
therapy, hormone therapy, and combined chemo-hormo-Page 7 of 8
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BMC Cancer 2009, 9:127 http://www.biomedcentral.com/1471-2407/9/127nal therapy, to patients who may be in cognitive and
emotional overload. While Adjuvant! is a well-validated
prognostic tool, its interface was initially intended to be
used by oncologists using it as a reference, not as an edu-
cational intervention. Our study suggests a need for con-
tinued improvement in the communication of breast
cancer therapy recurrence and survival risks.
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